ライフサイエンスコーパス: transgenic mouse

1 roliferative capacity in a conditional FIH-1 transgenic mouse.

2 f spontaneous EAE in the 2D2 T cell receptor transgenic mouse (2D2(+) mouse) that presents with hind-

3 we used an autoimmune-prone T-cell receptor transgenic mouse (2D2) and a mouse-adapted human influen

4 Differential staining of transgenic mouse Abeta amyloid plaque cores compared to

5 Hyperspectral imaging of transgenic mouse Abeta plaque stained with uncharged par

6 We created and validated a new transgenic mouse, alphaMHC (alpha myosin heavy chain)-Me

7 This transgenic mouse also provides an inducible and reversib

8 telangiectasia-mutated (ATM) signaling in HD transgenic mouse and cell models.

9 We create the first patient inspired KCNJ2 transgenic mouse and study effects of this mutation on c

10 cular, electrophysiological, behavioral, and transgenic mouse approaches were used to characterize MC

11 els expressing human ACE2, such as the hACE2 transgenic mouse, are also likely to be useful models fo

12 uencing analyses using the Rds/Prph2 (P216L) transgenic mouse as a preclinical model for retinitis pi

13 aque morphology in the cerebellum in APP/PS1 transgenic mouse, as a model of AD.

14 othelial enhancers, which we validated using transgenic mouse assays.

15 The pLckCre transgenic mouse available from The Jackson Laboratory,

16 man basophils and the human FcepsilonRIalpha transgenic mouse bone marrow-derived mast cells via driv

17 termine effective ultrasound parameters in a transgenic mouse brain slice model that enables calcium

18 ring protocols with the FACT protocol, using transgenic mouse brains with fluorochrome expression in

19 , tau expression was elevated in TDP-43M337V transgenic mouse brains.

20 stases in the mammary tumor virus (MMTV)-Neu transgenic mouse breast cancer model.

21 Here, we studied a transgenic mouse carrying the HD mutation with a repeat

22 Using brief (3 h) exposure of TCR-transgenic mouse CD8 T cells in vitro to varying densiti

23 Functional studies in transgenic mouse cells show that XACT influences XIST ac

24 A transgenic mouse containing a CRE-recombinase inducible

25 the tamoxifen inducible Hnf1b:CreER(T2) (H) transgenic mouse crossed to the LsL-Kras(G12D) (K) trans

26 Using pre-melanosome protein (Pmel)-Trx1 transgenic mouse-derived splenic T cells, flow cytometry

27 The Emu-TCL1 transgenic mouse develops a form of leukemia that is sim

28 The adult K/BxN transgenic mouse develops spontaneous autoimmune arthrit

29 ule dynamics at single granule resolution in transgenic mouse eggs.

30 tations in the cII gene from lambda phage in transgenic mouse embryonic fibroblasts during the transi

31 algorithms using single cells from Etv2-EYFP transgenic mouse embryos and reveal specific molecular p

32 ants robustly drove expression in the SAN of transgenic mouse embryos.

33 IR) on wild-type and p53 mutant cells in the transgenic mouse esophagus.

34 In vivo transgenic mouse experiments validate the cell type spec

35 sangial cells and in an inducible human Nox5 transgenic mouse exposed to streptozotocin-induced diabe

36 To address this, we created a transgenic mouse expressing H3.3K27M in diverse progenit

37 We have generated a novel transgenic mouse expressing human asyn in LC neurons to

38 this article, we report the development of a transgenic mouse expressing human CD22 (hCD22) in B cell

39 vivo cerebral ischemia model, we developed a transgenic mouse expressing human CD39 (hCD39).

40 Here we report a novel transgenic mouse expressing human wild-type asyn under c

41 current issue, Wei and colleagues describe a transgenic mouse expressing Plaur RNA in glomerular podo

42 we studied a bacterial artificial chromosome transgenic mouse expressing the A30P SNCA familial PD po

43 preimplantation development, we generated a transgenic mouse expressing the ERK kinase translocation

44 e same genetic approach in a newly described transgenic mouse expressing the human TDP-43 locus harbo

45 reviously explored in vivo mitophagy using a transgenic mouse expressing the mitochondria-targeted fl

46 Here we use a transgenic mouse-expressing POP2 controlled by its endog

47 B (gB(498-505), gB) in C57BL/6 mice using a transgenic mouse (gBT-I.1) model vaccinated with HSV-1 0

48 we successfully developed a SARS-CoV-2 hACE2 transgenic mouse (HFH4-hACE2 in C3B6 mice) infection mod

49 otentiation and long-term depression in USP6 transgenic mouse hippocampi.

50 al growth factor (EGFR)/ERK pathway in SORLA transgenic mouse hippocampus from both genders.

51 ion of PR3 in vivo, we generated a human PR3 transgenic mouse (hPR3Tg).

52 We generated a transgenic mouse in which channelrhodopsin-2 (ChR2) is c

53 Using a newly generated transgenic mouse in which PSCs are specifically labeled,

54 Using a transgenic mouse in which the promoter for the 5-HT3a su

55 developed a bacterial artificial chromosome transgenic mouse, in which expression of a red fluoresce

56 human ubiquitin C promoter (UBC)-driven-GFP transgenic mouse is a commonly used source of donor cell

57 The TH-MYCN transgenic mouse is a promising in vivo model for testin

58 Platelet factor 4-Cre recombinase (Pf4-Cre) transgenic mouse is the current model of choice for gene

59 Knockdown of claudin-16 gene expression in transgenic mouse kidney delocalizes Trpv5 from the lumin

60 endent adeno-associated virus in an Rbp4-Cre transgenic mouse line (both sexes) to label these L5 eff

61 duced CNS alphaS pathology in another alphaS transgenic mouse line (M20), albeit less robustly in the

62 The first PDE4B-transgenic mouse line (TG15) had a ~15-fold increase in

63 In the second PDE4B-transgenic mouse line (TG50), markedly higher PDE4B over

64 Therefore, we established a transgenic mouse line and performed an array of anatomic

65 These results establish the H3.3-HA transgenic mouse line as a compelling molecular barcodin

66 For this purpose, we first validated a transgenic mouse line expressing cre recombinase in hist

67 Here, we generate a new transgenic mouse line expressing equal ratios of 3R and

68 HA and LA, demonstrating the utility of this transgenic mouse line for identifying important factors

69 islabeled neuron population in a widely used transgenic mouse line in which GABAergic somatostatin-ex

70 orphism arises early in development, using a transgenic mouse line in which the expression of fluores

71 High expression of Tpm S283D variant in one transgenic mouse line resulted in an increased heart:bod

72 Furthermore, a transgenic mouse line specifically labeling SL cells sho

73 We established a transgenic mouse line that enabled the genetic interroga

74 y used as fundamental material brains from a transgenic mouse line that expresses LacZ under the cont

75 during ALS pathogenesis by crossing the new transgenic mouse line that overexpresses Cdk5 inhibitory

76 roposed mechanism, we created a controllable transgenic mouse line that sustains cortical MET signali

77 Using a novel transgenic mouse line to model the impact of human APP (

78 We report the development of a transgenic mouse line where Cre-recombinase-induced expr

79 With the use of a transgenic mouse line with conditional ablation of the m

80 Here, using a transgenic mouse line with destabilized GFP, we identifi

81 With the use of a transgenic mouse line, optical clearing, and imaging tec

82 Using an MrgprC11(CreERT2) transgenic mouse line, we labeled a small subset of itch

83 ith Cre-dependent eYFP or mCherry, using two transgenic mouse lines (including both sexes) that expre

84 e demonstrate that Nes-gfp and Nes-CreER(T2) transgenic mouse lines are novel tools for studying the

85 In combination with transgenic mouse lines expressing Cre or Flp recombinase

86 To address this hypothesis, we generated transgenic mouse lines harboring a Gata1 bacterial artif

87 ce of Tpm phosphorylation, here we generated transgenic mouse lines having a phosphomimetic substitut

88 s from six visual areas, four layers, and 12 transgenic mouse lines in a total of 243 adult mice, in

89 f EYFP(Vglut2) , EYFP(Vgat) , and GFP(Gad67) transgenic mouse lines revealed that, like GnRH neurons,

90 of the GARPs, we have characterized several transgenic mouse lines selectively restoring GARPs on a

91 We used HVEM(-/-) mice to establish three transgenic mouse lines that express either human WT HVEM

92 ression drives tumorigenesis, we established transgenic mouse lines that ubiquitously express increas

93 al expression system, here we generated Plk1 transgenic mouse lines to examine the role of Plk1 in tu

94 ablish bacterial artificial chromosome (BAC)-transgenic mouse lines with biased mTEC(lo) or mTEC(hi)

95 ion in human cardiac tissues and developed 2 transgenic mouse lines with cardiomyocyte-specific overe

96 We used three different transgenic mouse lines, each of which labels a subset of

97 mic cell types and subclasses using the same transgenic mouse lines.

98 on in three independent ThPOK overexpressing transgenic mouse lines.

99 ransgene insertion sites from 40 highly used transgenic mouse lines.

100 es, and iron metabolic genes in SCD Berkeley transgenic mouse lungs compared with controls.

101 Using a Ret transgenic mouse melanoma model, we found an accumulatio

102 ty and the formation of amyloid plaques in a transgenic mouse model (5xFAD) of early amyloid depositi

103 We generated a transgenic mouse model (EAAT3(glo)) to achieve condition

104 ire breadth to a non-self-antigen, a TCRbeta transgenic mouse model (EF4.1) expressing a limited, yet

105 ntration in vivo, we developed a conditional transgenic mouse model (Flpo/Frt system) expressing bioa

106 el, Hi-Myc mice, with a liver-specific IGF-1 transgenic mouse model (HIT) to increase their circulati

107 l cognitive assessment (water maze) in an AD transgenic mouse model (PS2APP) from 8 to 13 mo of age,

108 udied the contribution of REST to MB using a transgenic mouse model (RESTTG ) wherein conditional Neu

109 f Tau and neurofilament (NF) proteins in ALS transgenic mouse model (SOD1G37R).

110 o brain slice culture model for CWD, using a transgenic mouse model (Tg12) that expresses the elk (Ce

111 in human tau overexpressing line 66 mice, a transgenic mouse model akin to genetic variants of front

112 Here, using a transgenic mouse model and primary cell cultures along w

113 fects of soticlestat were characterized in a transgenic mouse model carrying mutated human amyloid pr

114 sphoribosyltransferase locus, we generated a transgenic mouse model containing the human renin (hREN)

115 In the present study, the first transgenic mouse model expressing dog prion protein (PrP

116 Here we show in a transgenic mouse model expressing mutant human tau predo

117 In a new transgenic mouse model fluorescent reporter protein expr

118 blockade in the K14cre;Cdh1(F/F);Trp53(F/F) transgenic mouse model for breast cancer stimulates intr

119 A transgenic mouse model for congenital stationary night b

120 he advantages and limitations of the HLA-DR4 transgenic mouse model for evaluating human C. trachomat

121 Using a transgenic mouse model for the sonic hedgehog (Shh) subg

122 Using a transgenic mouse model in which FlnA is selectively depl

123 severative behaviors, we characterized a new transgenic mouse model in which inducible ablation of SC

124 o address this gap, we developed a new IL-33 transgenic mouse model in which overexpression of full-l

125 V-induced skin carcinogenesis, we utilized a transgenic mouse model in which the keratin 14 promoter

126 This hAS transgenic mouse model is therefore an ideal animal mode

127 ivery in both wild type mice and the NSG-PiZ transgenic mouse model of AAT deficiency.

128 uppress the Alzheimer's-like phenotypes in a transgenic mouse model of Abeta deposition.

129 es over the course of neurodegeneration in a transgenic mouse model of AD (3xTg-AD).

130 of Western diet (WD) on female EFAD mice, a transgenic mouse model of AD that includes human APOE al

131 hemorrhage, ameliorates AD pathogenesis in a transgenic mouse model of AD.

132 synapse loss and for learning deficits in a transgenic mouse model of AD.

133 we confirm these results in vivo by using a transgenic mouse model of AD.

134 Mechanistic analysis was undertaken in a transgenic mouse model of ALS, where we find similar mar

135 subsequent fluorescent amyloid staining in a transgenic mouse model of Alzheimer's disease (tgSwe).

136 A transgenic mouse model of Anks1b haploinsufficiency reca

137 we report the characterization of the first transgenic mouse model of ARVC5.

138 are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by

139 results in suppression of tumour growth in a transgenic mouse model of breast cancer.

140 igated the impact of gammadelta T cells in a transgenic mouse model of carcinogenesis induced by HPV1

141 METHODS AND Using a transgenic mouse model of cardiac lipotoxicity overexpre

142 th plaque deposition and neuronal death in a transgenic mouse model of cerebral beta-amyloidosis.

143 We used a transgenic mouse model of chronic lung disease induced b

144 We generated a transgenic mouse model of CMT2A that developed severe ea

145 vivo relevance of this pathway in our IL-15 transgenic mouse model of CTCL by showing that interfere

146 GMP signaling.SIGNIFICANCE STATEMENT In DYT1 transgenic mouse model of dystonia, PDE10A, a key enzyme

147 ion and cardiac metabolism are affected in a transgenic mouse model of enhanced cardiac glycolysis (G

148 Hepatitis B X protein transgenic mouse model of HCC recapitulates this paradig

149 ilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle

150 ing required Bcl2-mediated autophagy using a transgenic mouse model of impaired inducible autophagy (

151 Using a human islet amyloid polypeptide transgenic mouse model of islet amyloidosis, we show ARC

152 ymal transition and metastasis, an MMTV-PyMT transgenic mouse model of mammary tumour progression and

153 non of reduced OEMVs was again observed in a transgenic mouse model of multiple system atrophy and in

154 patients and reduced IGF-1 brain levels in a transgenic mouse model of multiple system atrophy.

155 Here, we report that in a transgenic mouse model of MYC-induced T-cell leukemia, M

156 Using a "humanized" transgenic mouse model of nasal colonization, we took a

157 Using a transgenic mouse model of Parkinson's disease (PD) that

158 res, as well as in transgenic mice and a non-transgenic mouse model of PD.

159 our results show in an aggressively growing transgenic mouse model of PDAC that the coordinated acti

160 nic adenocarcinoma of mouse prostate (TRAMP) transgenic mouse model of prostate cancer.

161 In a transgenic mouse model of resectable PDAC, we investigat

162 and autoimmune kidney disease in the Tlr7.1 transgenic mouse model of SLE.

163 al deletion of Ldb1 in thymocytes in an Lmo2 transgenic mouse model of T-ALL.

164 Moreover, in a relevant transgenic mouse model of tauopathy, down-regulation of

165 s, neuroinflammation, neurodegeneration in a transgenic mouse model of tauopathy.

166 endritic metaplasticity is dysregulated in a transgenic mouse model of the disease, either before or

167 We have developed a transgenic mouse model of Type 1 Diabetes (T1D) in which

168 odegeneration remain unclear, we generated a transgenic mouse model of UCH-L1 deficiency.

169 in DIV7 cortical cultures of either from E18 transgenic mouse model or from rat E18 embryos that were

170 Aha1 overexpression in the rTg4510 tau transgenic mouse model promoted insoluble and oligomeric

171 Previous studies described a TDP-43(A315T) transgenic mouse model that develops progressive motor d

172 In the current studies, we identified a transgenic mouse model that exhibited a dysplastic coron

173 Here, we have generated a double-transgenic mouse model that expresses human CD1b and CD1

174 Our transgenic mouse model that expresses LacZ reporter unde

175 We created a transgenic mouse model that expresses the pH-dependent f

176 Using a powerful, inducible transgenic mouse model that overexpresses miR-155 and de

177 Here we used a novel transgenic mouse model to compare the spatial distributi

178 In this issue of the JCI, Pham et al. use a transgenic mouse model to demonstrate that STAT5BN642H i

179 gionally restricted and temporally regulated transgenic mouse model to investigate the behavioral, mo

180 We developed a triple-transgenic mouse model to map the fate of NG2(+)CD146(+)

181 We used a transgenic mouse model to show that the loss of presenta

182 This study used a cardiac-specific VCP transgenic mouse model to understand the transcriptomic

183 We generated an autochthonous transgenic mouse model whereby conditional expression of

184 A transgenic mouse model with elevated skeletal muscle 2-d

185 e, we studied retroviral susceptibility in a transgenic mouse model with lifelong innate immune syste

186 We accordingly generated a novel transgenic mouse model with this EGFP expression vector

187 We showed that in a transgenic mouse model, activation of the UPR in early d

188 In a somatic transgenic mouse model, depletion of Bcl6 inhibits the p

189 In the MMTV-Delta16HER2 transgenic mouse model, oncogene transformation resulted

190 e therapeutic profile of CpG ODN in a triple transgenic mouse model, Tg-SwDI, with abundant vascular

191 eloped bacterial artificial chromosome (BAC)-transgenic mouse model, we demonstrate that Lgr5 express

192 d precursor protein (APP)/presenilin 1 (PS1) transgenic mouse model, we found that inhibition of RIPK

193 Using our transgenic mouse model, we found that tetherin expressio

194 imeric cell-cell fusion assays, and a Sema3a transgenic mouse model, we identify Sema3a-Nrp1 signalin

195 Using an IL-27 reporter transgenic mouse model, we show in this study that conve

196 Here, in a transgenic mouse model, we show that deletion of the gen

197 Here, using a tissue-specific miRNA transgenic mouse model, we show that interaction between

198 Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of t

199 Herein, we use a novel transgenic mouse model, where doxycycline-induced overex

200 anied by visual deficits in a tie2-TNF-alpha transgenic mouse model.

201 on of USP6 enhances learning and memory in a transgenic mouse model.

202 modifier identified by the screen-in an APP transgenic mouse model.

203 with cognitive improvements in an AD APP/PS1 transgenic mouse model.

204 attenuate acute colitis in a humanized IL-26 transgenic mouse model.

205 ed Jagged1 using osteoblast-specific Jagged1 transgenic mouse model.

206 stemic anaphylaxis in human FcepsilonRIalpha transgenic mouse model.

207 n-target/off-tumor toxicity in a human CD147 transgenic mouse model.

208 epox/ectromelia virus (ECTV)-infection, B7.2 transgenic mouse model.

209 anamide, was investigated in the brain of AD transgenic mouse models (FAD) on an APOE4 or APOE3 genet

210 overcome these limitations, we combined here transgenic mouse models and proteomic analyses in order

211 dividual B cell clones from two distinct BCR transgenic mouse models but is dispensable for all of th

212 Studying the EPR in transgenic mouse models can define exact mechanisms of t

213 t composition in the skin, we have generated transgenic mouse models for tamoxifen-inducible de novo

214 f the problem with AD drug discovery is that transgenic mouse models have been poor predictors of pot

215 ine phosphatases Shp1 and Shp2, knockout and transgenic mouse models have revealed distinct phenotype

216 injury pharmacologically and genetically in transgenic mouse models in which microglia and systemic

217 Vs, and synthesize preclinical findings from transgenic mouse models of 16p11.2 CNVs.

218 Lesions of the LC in amyloid-based transgenic mouse models of AD exacerbate Abeta pathology

219 s amyloid aggregation in cells, worms and in transgenic mouse models of Alzheimer's disease.

220 tigated behavioral and pathologic changes in transgenic mouse models of amyotrophic lateral sclerosis

221 Existing transgenic mouse models of DYT11 exhibit only mild motor

222 odeled acquired resistance to osimertinib in transgenic mouse models of EGFR(L858R) -induced lung ade

223 breast cancer metastasis in two conditional transgenic mouse models of PyMT-induced breast cancer.

224 oters, and disruption of endogenous genes in transgenic mouse models of tauopathy make it difficult t

225 s mutant SOD1 expression is recapitulated in transgenic mouse models of the disease.

226 VIPR2 bacterial artificial chromosome (BAC) transgenic mouse models of VIPR2 CNV.

227 t the generation of Alzheimer's disease (AD) transgenic mouse models on a panel of 28 background stra

228 To address this gap, we developed two transgenic mouse models on the C57BL/6 background by ove

229 The PRMT overexpression transgenic mouse models should encourage and facilitate

230 Transgenic mouse models showed that norepinephrine dysre

231 Evidence from transgenic mouse models suggests mutant forms of FUS exe

232 The use of transgenic mouse models targeting either whole ERalpha i

233 Here, we provide evidence from transgenic mouse models that Crebbp deletion results in

234 Here, we used the Vav1 promoter to generate transgenic mouse models that expressed either human STAT

235 s neuron population, and employed additional transgenic mouse models to assess the role of one specif

236 We utilized knockin and transgenic mouse models to evaluate the structural, func

237 ell type-specific loss- and gain-of-function transgenic mouse models to investigate the physiologic r

238 Despite the extensive use of transgenic mouse models to investigate the propagation o

239 The authors used transgenic mouse models to show that claudin-2 deficienc

240 METHODS AND To address the question, 2 transgenic mouse models were generated: a phospho-mimeti

241 er-induced choroidal neovascularization, and transgenic mouse models with deficient or spontaneous re

242 Employing skeletal muscle-specific transgenic mouse models with unbiased-omic approaches, w

243 Using transgenic mouse models, these results demonstrate that

244 Using transgenic mouse models, we demonstrate that lymphatic e

245 Using transgenic mouse models, we investigated the effect of S

246 y and cognition in novel genetically matched transgenic mouse models, we surprisingly found that nonm

247 ical alternative to conditional knockout and transgenic mouse models.

248 etic screen were fulfilled in our studies of transgenic mouse models.

249 kout mouse lines in addition to the existing transgenic mouse models.

250 To this end, we created two transgenic mouse models; the iMS-Nrf2(flox/flox) and iMS

251 oluble form of SORLA (sSORLA) is observed in transgenic mouse neurons overexpressing human SORLA, whi

252 In a transgenic mouse of redox dysregulation carrying a perma

253 2 mice) in relation to a genetically matched transgenic mouse overexpressing nonmutant (NM) 4-repeat

254 To address this gap, here we developed a transgenic mouse overexpressing Sulf2 in hepatocytes und

255 This study used a novel transgenic mouse paradigm to ablate proliferating NG2(+)

256 eam effectors Grp78/BiP and eIF2alpha in ERG transgenic mouse prostate glands indicate the presence o

257 Epithelial cells derived from ERG transgenic mouse prostates have increased prostasphere f

258 NF-kappaB signalling-deficient IkappaBDeltaN transgenic mouse rescues NKT cell development and differ

259 We generated FSP-1-specific p90RSK transgenic mouse (RSK-Tg) and discovered that these mice

260 A transcript was barely changed in the fat-1 transgenic mouse skin.

261 del we used wild-type MMTV mice and a triple transgenic mouse SPC-rtTA(+/-)TetoCre(+/-)LoxP-VEGF-A(+/

262 HLA-A*11:01, HLA-A*02:01, and HLA-B*07:02q11 transgenic mouse splenocytes with peptides demonstrated

263 Using a transgenic mouse strain expressing the human V(H)1-69 ge

264 vercome this issue, we developed a Gp1ba-Cre transgenic mouse strain in which Cre expression is drive

265 navigate these constrictions, we developed a transgenic mouse strain that expresses a photoactivatabl

266 We use a transgenic mouse strain that ubiquitously expresses a mo

267 ated with ALDH7A1 deficiency, we generated a transgenic mouse strain with constitutive genetic ablati

268 rlies increased pain behaviors in the Possum transgenic mouse strain.

269 s via a doxycycline (Dox)-inducible compound transgenic mouse strain.

270 Using three transgenic mouse strains having mutated deoxyhemoglobin-

271 We utilized transgenic mouse strains that either constitutively expr

272 h the use of diphtheria toxin receptor (DTR) transgenic mouse strains to deplete various APCs, we fou

273 Furthermore, using different Cre-recombinase transgenic mouse strains to specifically target CD1d def

274 of mapping the transgene integration site of transgenic mouse strains used in biomedical research.

275 Transgenic mouse studies confirmed that donor islet-spec

276 Transgenic mouse studies establish PRKCI as an ovarian c

277 lecule prolongs the half-life in a human CD4 transgenic mouse, suggesting that it may have potential

278 this study, we analyzed these processes in a transgenic mouse system in which TCR-transgenic Th cells

279 p in knowledge, we developed an H-2D(b) LoxP-transgenic mouse system using otherwise MHC class I-defi

280 Using advanced transgenic mouse technology, we show that IL-1-dependent

281 Using transgenic mouse technology, we show that Shp2 is involv

282 Here, we report a new transgenic mouse (termed SPASTC448Y mouse) that is not h

283 We recently developed the Deltap35KI transgenic mouse that is deficient in p25 generation and

284 We generated a transgenic mouse that is inducible and overexpresses SIR

285 nvolved in isotype switching, we generated a transgenic mouse that over-expressed RNase H1, an enzyme

286 l of the human TNF locus to generate a novel transgenic mouse, the hTNF.LucBAC strain.

287 the tau pathology observed in AD patient vs. transgenic mouse tissue.

288 g, imaging and mass spectrometry, we use our transgenic mouse to label and analyze proteins in excita

289 we generated a doxycycline suppressible Cre transgenic mouse under the regulation of the Nkx2.5 enha

290 Here, we utilized novel CHCHD10 transgenic mouse variants (WT, R15L, & S59L), TDP-43 tra

291 odynia, we generated and characterized a new transgenic mouse (Vglut1-ChR2) to optogenetically activa

292 1 channels in the cardiac pathophysiology, a transgenic mouse was generated with cardiomyocyte-specif

293 earing, or retrograde tracing in a MET(EGFP) transgenic mouse, we identify three novel subpopulations

294 enic mouse crossed to the LsL-Kras(G12D) (K) transgenic mouse, we recently discovered that an Hnf1b p

295 , we generated a FGFR gain-of-function (GOF) transgenic mouse, which expresses constitutively activat

296 a causative role in OA, we used the p16-3MR transgenic mouse, which harbors a p16(INK4a) (Cdkn2a) pr

297 A BAC transgenic mouse with functional hCFTR under control of

298 ted gene-1(AEG-1)/metadherin in NASH using a transgenic mouse with hepatocyte-specific overexpression

299 Methods: We generated a unique CD68.hMcl-1 transgenic mouse with macrophage-specific overexpression

300 fied subset markers, for the generation of a transgenic mouse would enable future studies of RGC-subt